Hepatitis C Virus (HCV)

CAS No.	Product Name	Inquiry
1416334-69-4	GSK-A1 GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research.
1423007-82-2	GSK8175 GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons.
1425038-27-2	MK-5172 sodium salt In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose.
1428729-63-8	RIG-1 modulator 1 RIG-1 modulator 1 is an inhibitor of HBV, HCV and HIV.
143188-53-8	Lamivudine Triphosphate 3TCTP is a dideoxynucleoside analog and an inhibitor of reverse transcriptase that exhibit antiviral effect in vivo.
143205-42-9	NIM811 NIM811 is a dual inhibitor of mitochondrial permeability transition and cyclophilin. It exhibits potent in vitro inhibitory activity against hepatitis C virus (HCV).
1449756-86-8	HCV-IN-7 HCV-IN-7, a potent and orally active pan-genotypic HCV NS5A inhibitor (IC50 of 3-47 pM) with antiviral activity, demonstrates superior pan-genotypic profile and good pharmacokinetic characteristics, as well as favorable liver uptake.
1449756-87-9	HCV-IN-7 dihydrochloride HCV-IN-7 hydrochloride, a potent and orally active pan-genotypic HCV NS5A inhibitor (IC50 of 3-47 pM) with antiviral activity, demonstrates superior pan-genotypic profile and good pharmacokinetic characteristics, as well as favorable liver uptake.
1456607-71-8	Paritaprevir-dihydrate Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor).
1496551-77-9	Uprifosbuvir Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus.
1496552-16-9	Sofosbuvir impurity A Sofosbuvir impurity A is a diastereoisomer and impurity of Sofosbuvir, an inhibitor of HCV RNA replication with strong anti-hepatitis C virus activity.
1496552-51-2	Chloro Sofosbuvir Chloro Sofosbuvir is an impurity of Sofosbuvir; a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled Sofosbuvir as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.
1502654-87-6	Ledipasvir D-tartrate Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.006 nM), A30V (EC(50) = 0.012 nM), and E92A (EC(50) = 0.004 nM) while the NS5A-A30K and -Y93H variants exhibited reduced sensitivity to DCV (EC50 values of 23 nM and 1120 nM, respectively) and to GS-5885 (EC50 values of 1770 nM and 4300 nM, respectively). GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Plasma pharmacokinetics was consistent with QD dosing.
1502655-48-2	Ledipasvir diacetone Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.006 nM), A30V (EC(50) = 0.012 nM), and E92A (EC(50) = 0.004 nM) while the NS5A-A30K and -Y93H variants exhibited reduced sensitivity to DCV (EC50 values of 23 nM and 1120 nM, respectively) and to GS-5885 (EC50 values of 1770 nM and 4300 nM, respectively). GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Plasma pharmacokinetics was consistent with QD dosing.
1509904-96-4	Cyclophilin inhibitor 1 Cyclophilin inhibitor 1 is a potent and orally bioavailable cyclophilin inhibitor, and it shows effective anti-HCV activity, with an EC50 of 98 nM for HCV 2a.
151271-53-3	UK-1 UK-1, a benzoxazol derivative, has been found to be a Streptomyces metabolite that could exhibit anticancer activity and topoisomerase II restraination activity.
1535212-07-7	Voxilaprevir Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity. Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively. Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research.
15397-12-3	2'-C-methyladenosine 2'-C-Methyladenosine is an inhibitor of hepatitis C virus (HCV) replication (IC50 = 0.3 µM in Huh-7 human hepatoma cells) that is not cytotoxic at concentrations up to 100 µM.
15574-49-9	Mecarbinate Mecarbinate is a chemical intermediate of arbidol hydrochloride.
1606150-08-6	BMS-986144 BMS-986144, a third-generation, pan-genotype (GT) NS3/4A protease inhibitor, inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively.

※ Please kindly note that our services are for research use only.